HHS Officials Raise Concerns About Pricing, Patent Restrictions for Medical Countermeasures
Executive Summary
US FDA Commissioner and Health and Human Services Assistant Secretary for Preparedness and Response cautioned against changes to rewards for medical countermeasure developers in the next Pandemic and All-Hazards Preparedness Act reauthorization that might discourage biotech companies from working with the government.
You may also be interested in...
US FDA Gets Wanted Pathogen Program, Manufacturers Get Longer BARDA Contracts In Competing Pandemic Prep Bills
Key House and Senate committees advanced reauthorizations of the Pandemic All-Hazards Preparedness Act. It is unclear whether new perks for the FDA and drug makers will survive as the two chambers reconcile a myriad of differences between their plans.
FDA – And Rx Supply Chain Resiliency – Strikeout In Senate’s Draft Pandemic Prep Bill
US FDA’s attempt to address drug shortage and supply chain weaknesses in the upcoming reauthorization of pandemic preparedness legislation looks unlikely as both chambers of Congress have now thrown wrenches in the plan.
Supplemental Filings: FDA Can't 'Plug' All Shortage Holes, New Jobs For Billy Dunn, Lisa Parks & Heidi Rebello
From infant formula to drugs, Califf can't get away from shortage work. Plus, the revolving door brings new jobs for some top pharma folks.